Skip to main content
padlock icon - secure page this page is secure

Outpatient assessment of residual growth hormone secretion in treated acromegaly with overnight urinary growth hormone excretion, random serum growth hormone and insulin like growth factor-1

Buy Article:

$59.00 + tax (Refund Policy)


To assess the outpatient investigations, overnight urinary growth hormone (uGH) excretion, random serum GH and insulin like growth factor 1 (IGF-1), and GH indices from the oral glucose tolerance test (OGTT) (fasting, nadir and mean GH), as measures of mean GH secretion in treated acromegaly, in comparison with a GH day series, which served as a gold standard. DESIGN

Prospective cross-sectional study, with patients admitted to a metabolic ward for the following investigations: random GH, IGF-1, 6 point GH day series (day 1), 9 h timed overnight uGH excretion, OGTT with GH response (day 2). Agreements between the mean GH during the day series and the other outcome measures, and the diagnostic performance of the latter, for the presence or absence of active acromegaly (mean GH during day series  5 or < 5 mU/l, respectively) were determined. PATIENTS

26 patients with treated acromegaly (11 with inactive acromegaly off drug therapy). MEASUREMENTS

Serum GH and uGH were measured by immunoradiometric assays and IGF-1 by radioimmunoassay. RESULTS

Agreements with the mean GH during the day series were perfect for the nadir GH during the OGTT with a 2 mU/l cutoff (Cohen's kappa (κ) = 1, P < 0.00001), almost perfect for the fasting and mean GH throughout the OGTT (both κ = 0.92, P < 0.0001) and random GH (κ = 0.85, P < 0.0001), and substantial for the nadir GH with a 5 mU/l cutoff (κ = 0.77, P < 0.0001), IGF-1 (κ = 0.62, P < 0.001) and overnight uGH excretion (κ = 0.61, P = 0.002). Nadir GH with a 2 mU/l cutoff was completely accurate for diagnosing the presence or absence of active acromegaly (positive and negative predictive values (% ± standard error percentage) 100 ± 8% and 100 ± 10%). None of the outpatient tests used alone was an adequate diagnostic test (positive and negative predictive values: overnight uGH excretion − 86 ± 10% and 75 ± 13%; random GH −100 ± 11% and 85 ± 11%; IGF-1 − 92 ± 10% and 71 ± 13%) and so combinations of tests were assessed. The best was overnight uGH excretion plus random GH (positive and negative predictive values 88 ± 9% and 100 ± 12%). Using all three outpatient investigations, the positive predictive value of three raised results was 100 ± 13%. CONCLUSIONS

In treated acromegaly, residual GH secretion can be reliably assessed with the OGTT, using standard diagnostic criteria. It can also be assessed on an outpatient basis with overnight uGH excretion and random GH, as direct measures, and IGF-1. If these are all normal, active acromegaly is excluded. Three raised results denote active acromegaly, and one or two raised results would need further investigation with a GH day series.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Document Type: Original Article

Affiliations: 1: Southampton Diabetes and Endocrinology Unit, Royal South Hants Hospital, Southampton, 2: Regional Endocrine Unit, Department of Chemical Pathology, Southampton General Hospital, Southampton, UK

Publication date: November 1, 1998

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more